Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients

Background : Pathophysiological changes such as extreme body weights in critically ill patients with severe infections may alter the pharmacokinetics (PK) of antimicrobials, leading to treatment failure or toxicity. There are almost no PK data on meropenem in critically ill patients with low body we...

Descripción completa

Detalles Bibliográficos
Autores: Luque, Sonia|||0000-0002-3215-320X, Benítez-Cano, Adela|||0000-0003-4794-5936, Larrañaga, Leire, Sorlí, Luisa|||0000-0001-9562-514X, Navarrete-Rouco, Maria Eugenia|||0000-0002-4684-5952, Campillo, Núria, Carazo, Jesús|||0000-0002-1912-7189, Ramos, Isabel, Adàlia, Ramon|||0009-0004-9458-1922, Grau, Santiago|||0000-0002-8428-1836
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:256449
Acceso en línea:https://ddd.uab.cat/record/256449
https://dx.doi.org/urn:doi:10.3390/antibiotics10060666
Access Level:acceso abierto
Palabra clave:Antibiotics
Pharmacokinetics
Pharmacodynamics
Low body weight
Meropenem
Descripción
Sumario:Background : Pathophysiological changes such as extreme body weights in critically ill patients with severe infections may alter the pharmacokinetics (PK) of antimicrobials, leading to treatment failure or toxicity. There are almost no PK data on meropenem in critically ill patients with low body weight (LwBW) and therefore information is lacking on the most appropriate dosing regimens, especially when administered by extended infusion. Objectives : To assess if the current administered doses of meropenem could lead to supratherapeutic concentrations in LwBW patients and to identify the factors independently associated with overexposure. Methods: A matched case-control 1:1 study of surgical critically ill patients treated with meropenem administered by extended or continuous infusion and undergoing therapeutic drug monitoring was conducted. Cases (patients with LwBW (body mass index (BMI) < 18.5 kg/m 2)) were matched with normal body weight controls (NBW) (patients with BMI ≥ 18.5 kg/m 2 and ≤30 kg/m 2)) by age, gender, baseline renal function and severity status (APACHE II score). A 100% fT.

Similares en LA Referencia